Drug Approval | May 25, 2024
Zydus receives final approval from USFDA for Theophylline ER Tablets
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Subscribe To Our Newsletter & Stay Updated
